ChemoMetec revenue rises 3%, EBITDA margin improves
ChemoMetec said revenue increased 3% to DKK 511 million, helped by strong XcytoMatic instrument sales, and EBITDA margin improved to 55%.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.